- Revenue of $3,636 million for the fourth quarter grew 10.2
percent year-over-year on a reported basis and 11.6 percent at
constant currency
- GAAP Net Income of $318 million for the fourth quarter grew
167.2 percent year-over-year
- Adjusted EBITDA of $828 million for the fourth quarter grew
12.7 percent year-over-year
- GAAP Diluted Earnings per Share of $1.63 for the fourth
quarter grew 167.2 percent year-over-year
- Adjusted Diluted Earnings per Share of $2.55 for the fourth
quarter grew 20.9 percent year-over-year
- Full-year Operating Cash Flow of $2,942 million grew 50.2
percent year-over-year and record full-year Free Cash Flow of
$2,302 million grew 71.4 percent year-over-year
- Record R&D Solutions contracted backlog of $24.8 billion
grew 10.2 percent year-over-year
- Share repurchase authorization increased by $2.0 billion in
February 2022
- Full-year 2022 guidance reaffirmed for revenue including a
$70 million revenue headwind from foreign exchange
- Full-year 2022 guidance raised for Adjusted EBITDA and
Adjusted Diluted EPS
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global
provider of advanced analytics, technology solutions, and clinical
research services to the life sciences industry, today reported
financial results for the quarter ended December 31, 2021.
Fourth-Quarter 2021 Operating Results
Revenue for the fourth quarter of $3,636 million increased 10.2
percent on a reported basis and 11.6 percent at constant currency,
compared to the fourth quarter of 2020. Technology & Analytics
Solutions (TAS) revenue of $1,496 million grew 5.0 percent on a
reported basis and 6.6 percent at constant currency. Research &
Development Solutions (R&DS) revenue of $1,944 million grew by
15.4 percent on a reported basis and by 16.3 percent at constant
currency. Excluding the impact of pass throughs, R&DS revenue
grew 17.1 percent year-over-year on a reported basis. Contract
Sales & Medical Solutions (CSMS) revenue of $196 million grew
by 3.7 percent on a reported basis and by 7.4 percent at constant
currency.
R&DS contracted backlog, including reimbursed expenses, grew
10.2 percent year-over-year to $24.8 billion as of December 31,
2021. The company expects approximately $7.0 billion of this
backlog to convert to revenue in the next twelve months. The
fourth-quarter as-contracted net book-to-bill ratio was 1.36x
excluding reimbursed expenses and 1.24x including reimbursed
expenses. For the year ended December 31, 2021, the as-contracted
net book-to-bill ratio was 1.35x excluding reimbursed expenses and
1.34x including reimbursed expenses.
"We closed 2021 with an impressive quarter, delivering robust
growth across all key financial metrics versus what was a strong
fourth quarter of 2020," said Ari Bousbib, chairman and CEO of
IQVIA. "We had a record year of net new business in R&DS,
strong double-digit revenue growth for the year in both our
R&DS and TAS segments, and a record year of free cash flow
generation. We are now two-thirds of the way through our Vision 22
plan and are on a path to achieving or exceeding our targets. The
outlook for our end markets remains favorable and we expect
continued strong demand for our differentiated offerings in 2022.
Looking beyond 2022 to the next phase of our growth, we are well
positioned to achieve our ambitious 2025 targets."
Fourth-quarter GAAP net income was $318 million, representing an
increase of 167.2 percent compared to the fourth quarter of 2020,
and GAAP diluted earnings per share was $1.63, representing an
increase of 167.2 percent year-over-year. Adjusted Net Income was
$496 million, up 20.7% year-over-year, and Adjusted Diluted
Earnings per Share was $2.55, up 20.9 percent year-over-year.
Adjusted EBITDA was $828 million, up 12.7 percent compared to the
fourth quarter of 2020.
Full-Year 2021 Operating Results
Revenue of $13,874 million for the full year of 2021 grew 22.1
percent on a reported basis and 21.1 percent at constant currency,
compared to 2020. TAS revenue was $5,534 million, up 13.9 percent
reported and 12.4 percent at constant currency. R&DS revenue
was $7,556 million, up 31.2 percent on a reported basis and 30.4
percent at constant currency. CSMS revenue was $784 million, up 5.8
percent reported and 5.7 percent at constant currency.
For the full year of 2021, GAAP net income was $966 million, up
246.2 percent year-over-year, and GAAP diluted earnings per share
was $4.95, up 246.2 percent year-over-year. Adjusted Net Income was
$1,760 million, up 40.6 percent year-over-year, and Adjusted
Diluted Earnings per Share was $9.03, up 40.7 percent
year-over-year. Adjusted EBITDA for the full year of 2021 was
$3,022 million, up 26.8 percent year-over-year.
Financial Position
As of December 31, 2021, cash and cash equivalents were $1,366
million and debt was $12,125 million, resulting in net debt of
$10,759 million. At the end of the fourth quarter of 2021, IQVIA’s
Net Leverage Ratio was 3.6x trailing twelve month Adjusted EBITDA.
For the fourth quarter of 2021, Operating Cash Flow was $692
million and Free Cash Flow was $508 million. For the full year of
2021, Operating Cash Flow was $2,942 million and Free Cash Flow was
$2,302 million.
Share Repurchase
During the fourth quarter of 2021, the company repurchased $174
million of its common stock, resulting in full year share
repurchases of $395 million. IQVIA had $523 million of share
repurchase authorization remaining as of December 31, 2021.
On February 10, 2022, the IQVIA board approved an increase of
the share repurchase authorization by $2.0 billion, bringing the
remaining authorization to just over $2.5 billion.
Full-Year 2022 Guidance
For the full year of 2022, the company is reaffirming the
revenue guidance range of $14,700 million to $15,000 million
provided at its Analyst and Investor Conference in November 2021,
despite a $70 million revenue headwind from changes in foreign
currency exchange rates since the issuance of the company's
previous guidance. This revenue guidance implies revenue growth of
7.1% to 9.2% at constant currency and 6.0% to 8.1% on a reported
basis. For the full year of 2022, the company is raising the
Adjusted EBITDA and Adjusted Diluted EPS guidance ranges provided
at its Analyst and Investor Conference in November 2021. The
company now expects Adjusted EBITDA to be between $3,330 million
and $3,405 million, and Adjusted Diluted Earnings per Share to be
between $9.95 and $10.25, representing growth of 10.2% to 12.7% and
10.2% to 13.5% on a reported basis, respectively.
First-Quarter 2022 Guidance
For the first quarter of 2022, the company expects revenue to be
between $3,515 million and $3,575 million, representing growth of
4.8% to 6.6% at constant currency and 3.1% to 4.9% on a reported
basis. The company expects Adjusted EBITDA to be between $800
million and $815 million, and Adjusted Diluted Earnings per Share
to be between $2.40 and $2.46, representing growth of 7.5% to 9.5%
and 10.1% to 12.8% on a reported basis, respectively.
All financial guidance assumes foreign currency exchange rates
as of December 31, 2021 remain in effect for the forecast
period.
Webcast & Conference Call Details
IQVIA will host a conference call at 9:00 a.m. Eastern Time
today to discuss its fourth-quarter and full-year 2021 results and
its first-quarter and full-year 2022 guidance. To listen to the
event and view the presentation slides via webcast, join from the
IQVIA Investor Relations website at http://ir.iqvia.com. To
participate in the conference call, interested parties must
register in advance by clicking on this link. Following
registration, participants will receive a confirmation email
containing details on how to join the conference call, including
the dial-in and a unique passcode and registrant ID. At the time of
the live event, registered participants connect to the call using
the information provided in the confirmation email and will be
placed directly into the call.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 79,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
Cautionary Statements Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the federal securities laws, including Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including, without
limitation, our first-quarter and full-year 2022 guidance. In this
context, forward-looking statements often address expected future
business and financial performance and financial condition, and
often contain words such as “expect,” “assume,” “anticipate,”
“intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,”
“would,” “target,” similar expressions, and variations or negatives
of these words that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
our expectations due to a number of factors, including, but not
limited to, the following: business disruptions caused by natural
disasters, pandemics such as the COVID-19 (coronavirus) outbreak,
including any variants, and the public health policy responses to
the outbreak, international conflicts or other disruptions outside
of our control; our ability to accurately model or forecast the
impact of the spread and/or containment of COVID-19, including any
variants, among other sources of business interruption, on our
operations and financial results; most of our contracts may be
terminated on short notice, and we may lose or experience delays
with large client contracts or be unable to enter into new
contracts; the market for our services may not grow as we expect;
we may be unable to successfully develop and market new services or
enter new markets; imposition of restrictions on our use of data by
data suppliers or their refusal to license data to us; any failure
by us to comply with contractual, regulatory or ethical
requirements under our contracts, including current or future
changes to data protection and privacy laws; breaches or misuse of
our or our outsourcing partners’ security or communications
systems; failure to meet our productivity or business
transformation objectives; failure to successfully invest in growth
opportunities; our ability to protect our intellectual property
rights and our susceptibility to claims by others that we are
infringing on their intellectual property rights; the expiration or
inability to acquire third party licenses for technology or
intellectual property; any failure by us to accurately and timely
price and formulate cost estimates for contracts, or to document
change orders; hardware and software failures, delays in the
operation of our computer and communications systems or the failure
to implement system enhancements; the rate at which our backlog
converts to revenue; our ability to acquire, develop and implement
technology necessary for our business; consolidation in the
industries in which our clients operate; risks related to client or
therapeutic concentration; government regulators or our customers
may limit the scope of prescription or withdraw products from the
market, and government regulators may impose new regulatory
requirements or may adopt new regulations affecting the
biopharmaceutical industry; the risks associated with operating on
a global basis, including currency or exchange rate fluctuations
and legal compliance, including anti-corruption laws; risks related
to changes in accounting standards; general economic conditions in
the markets in which we operate, including financial market
conditions and risks related to sales to government entities; the
impact of changes in tax laws and regulations; and our ability to
successfully integrate, and achieve expected benefits from, our
acquired businesses. For a further discussion of the risks relating
to our business, see the “Risk Factors” in our annual report on
Form 10-K for the fiscal year ended December 31, 2020, filed with
the Securities and Exchange Commission (the "SEC"), as such factors
may be amended or updated from time to time in our subsequent
periodic and other filings with the SEC, which are accessible on
the SEC’s website at www.sec.gov. These factors should not be
construed as exhaustive and should be read in conjunction with the
other cautionary statements that are included in this release and
in our filings with the SEC. We assume no obligation to update any
such forward-looking statement after the date of this release,
whether as a result of new information, future developments or
otherwise.
Note on Non-GAAP Financial Measures
This release includes information based on financial measures
that are not recognized under generally accepted accounting
principles in the United States ("GAAP"), such as Adjusted EBITDA,
Adjusted Net Income, Adjusted Diluted EPS, and Free Cash Flow.
Non-GAAP financial measures are presented only as a supplement to
the company’s financial statements based on GAAP. Non-GAAP
financial information is provided to enhance understanding of the
company’s financial performance, but none of these non-GAAP
financial measures are recognized terms under GAAP, and non-GAAP
measures should not be considered in isolation from, or as a
substitute analysis for, the company’s results of operations as
determined in accordance with GAAP. The company uses non-GAAP
measures in its operational and financial decision making, and
believes that it is useful to exclude certain items in order to
focus on what it regards to be a more meaningful indicator of the
underlying operating performance of the business. For example, the
Company excludes all the amortization of intangible assets
associated with acquired customer relationships and backlog,
databases, non-compete agreements and trademarks, trade names and
other from non-GAAP expense and income measures as such amounts can
be significantly impacted by the timing and size of acquisitions.
Although we exclude amortization of acquired intangible assets from
our non-GAAP expenses, we believe that it is important for
investors to understand that revenue generated from such
intangibles is included within revenue in determining net income
attributable to IQVIA Holdings Inc. As a result, internal
management reports feature non-GAAP measures and are used to
prepare strategic plans and annual budgets and review management
compensation. The company also believes that investors may find
non-GAAP financial measures useful for the same reasons, although
investors are cautioned that non-GAAP financial measures are not a
substitute for GAAP disclosures.
The non-GAAP financial measures are not presented in accordance
with GAAP. Please refer to the schedules attached to this release
for reconciliations of non-GAAP financial measures contained herein
to the most directly comparable GAAP measures. Our first-quarter
and full-year 2022 guidance measures (other than revenue) are
provided on a non-GAAP basis without a reconciliation to the most
directly comparable GAAP measure because the company is unable to
predict with a reasonable degree of certainty certain items
contained in the GAAP measures without unreasonable efforts. Such
items include, but are not limited to, acquisition related
expenses, restructuring and related expenses, stock-based
compensation and other items not reflective of the company's
ongoing operations.
Non-GAAP measures are frequently used by securities analysts,
investors and other interested parties in their evaluation of
companies comparable to the company, many of which present non-GAAP
measures when reporting their results. Non-GAAP measures have
limitations as an analytical tool. They are not presentations made
in accordance with GAAP, are not measures of financial condition or
liquidity and should not be considered as an alternative to profit
or loss for the period determined in accordance with GAAP or
operating cash flows determined in accordance with GAAP. Non-GAAP
measures are not necessarily comparable to similarly titled
measures used by other companies. As a result, you should not
consider such performance measures in isolation from, or as a
substitute analysis for, the company’s results of operations as
determined in accordance with GAAP.
IQVIAFIN
Table 1
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
INCOME
(preliminary and unaudited)
Three Months Ended December
31,
Twelve Months Ended December
31,
(in millions, except per share
data)
2021
2020
2021
2020
Revenues
$
3,636
$
3,298
$
13,874
$
11,359
Costs of revenue, exclusive of
depreciation and amortization
2,364
2,172
9,233
7,500
Selling, general and administrative
expenses
542
491
1,964
1,789
Depreciation and amortization
262
344
1,264
1,287
Restructuring costs
5
2
20
52
Income from operations
463
289
1,393
731
Interest income
(2
)
(2
)
(6
)
(6
)
Interest expense
90
102
375
416
Loss on extinguishment of debt
1
1
26
13
Other income, net
(2
)
(6
)
(130
)
(65
)
Income before income taxes and equity in
earnings (losses) of
unconsolidated affiliates
376
194
1,128
373
Income tax expense
59
63
163
72
Income before equity in earnings (losses)
of unconsolidated affiliates
317
131
965
301
Equity in earnings (losses) of
unconsolidated affiliates
1
(1
)
6
7
Net income
318
130
971
308
Net income attributable to non-controlling
interests
—
(11
)
(5
)
(29
)
Net income attributable to IQVIA Holdings
Inc.
$
318
$
119
$
966
$
279
Earnings per share attributable to common
stockholders:
Basic
$
1.67
$
0.62
$
5.05
$
1.46
Diluted
$
1.63
$
0.61
$
4.95
$
1.43
Weighted average common shares
outstanding:
Basic
190.8
191.5
191.4
191.3
Diluted
194.8
195.0
195.0
195.0
Table 2
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
(preliminary and unaudited)
December 31,
(in millions, except per share
data)
2021
2020
ASSETS
Cash and cash equivalents
$
1,366
$
1,814
Trade accounts receivable and unbilled
services, net
2,551
2,410
Prepaid expenses
156
159
Income taxes receivable
58
56
Investments in debt, equity and other
securities
111
88
Other current assets and receivables
521
563
Total current assets
4,763
5,090
Property and equipment, net
497
482
Operating lease right-of-use assets
406
471
Investments in debt, equity and other
securities
76
78
Investments in unconsolidated
affiliates
88
84
Goodwill
13,301
12,654
Other identifiable intangibles, net
4,943
5,205
Deferred income taxes
124
114
Deposits and other assets
491
386
Total assets
$
24,689
$
24,564
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities:
Accounts payable and accrued expenses
$
2,981
$
2,813
Unearned income
1,825
1,252
Income taxes payable
137
102
Current portion of long-term debt
91
149
Other current liabilities
207
242
Total current liabilities
5,241
4,558
Long-term debt, less current portion
12,034
12,384
Deferred income taxes
410
338
Operating lease liabilities
313
371
Other liabilities
649
633
Total liabilities
18,647
18,284
Stockholders’ equity:
Common stock and additional paid-in
capital, 400.0 shares authorized as of
December 31, 2021 and 2020, $0.01 par
value, 255.8 shares issued and 190.6 shares
outstanding as of December 31, 2021; 254.7
shares issued and 191.2 shares outstanding
as of December 31, 2020
10,777
11,095
Retained earnings
2,243
1,277
Treasury stock, at cost, 65.2 and 63.5
shares as of December 31, 2021 and 2020, respectively
(6,572
)
(6,166
)
Accumulated other comprehensive loss
(406
)
(205
)
Equity attributable to IQVIA Holdings
Inc.’s stockholders
6,042
6,001
Non-controlling interests
—
279
Total stockholders’ equity
6,042
6,280
Total liabilities and stockholders’
equity
$
24,689
$
24,564
Table 3
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CASH FLOWS
(preliminary and unaudited)
Year Ended
(in millions)
2021
2020
Operating activities:
Net income
$
971
$
308
Adjustments to reconcile net income to
cash provided by operating activities:
Depreciation and amortization
1,264
1,287
Amortization of debt issuance costs and
discount
17
18
Stock-based compensation
170
95
Earnings from unconsolidated
affiliates
(6
)
(7
)
Gain on investments, net
(16
)
(25
)
Benefit from deferred income taxes
(138
)
(176
)
Changes in operating assets and
liabilities:
Accounts receivable and unbilled
services
(138
)
255
Prepaid expenses and other assets
(15
)
(146
)
Accounts payable and accrued expenses
244
253
Unearned income
591
180
Income taxes payable and other
liabilities
(2
)
(83
)
Net cash provided by operating
activities
2,942
1,959
Investing activities:
Acquisition of property, equipment and
software
(640
)
(616
)
Acquisition of businesses, net of cash
acquired
(1,458
)
(177
)
Purchases of marketable securities,
net
(10
)
(9
)
Investments in unconsolidated affiliates,
net of payments received
(5
)
10
Proceeds from sale of (investments in)
equity securities
5
(2
)
Other
5
(2
)
Net cash used in investing activities
(2,103
)
(796
)
Financing activities:
Proceeds from issuance of debt
1,951
1,591
Payment of debt issuance costs
(40
)
(33
)
Repayment of debt
(2,091
)
(864
)
Proceeds from revolving credit
facility
810
1,250
Repayment of revolving credit facility
(600
)
(1,635
)
Payments related to employee stock option
plans
(59
)
(44
)
Repurchase of common stock
(406
)
(447
)
Distributions to non-controlling interest,
net
—
(13
)
Acquisition of Quest's non-controlling
interest
(758
)
—
Contingent consideration and deferred
purchase price payments
(42
)
(22
)
Net cash used in financing activities
(1,235
)
(217
)
Effect of foreign currency exchange rate
changes on cash
(52
)
31
(Decrease) increase in cash and cash
equivalents
(448
)
977
Cash and cash equivalents at beginning of
period
1,814
837
Cash and cash equivalents at end of
period
$
1,366
$
1,814
Table 4
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
NET INCOME TO ADJUSTED EBITDA
RECONCILIATION
(preliminary and unaudited)
Three Months Ended
Twelve Months Ended
December 31,
December 31,
(in millions)
2021
2020
2021
2020
Net Income Attributable to IQVIA
Holdings Inc.
$
318
$
119
$
966
$
279
Provision for income taxes
59
63
163
72
Depreciation and amortization
262
344
1,264
1,287
Interest expense, net
88
100
369
410
(Income) loss in unconsolidated
affiliates
(1
)
1
(6
)
(7
)
Income from non-controlling interests
—
11
5
29
Deferred revenue purchase accounting
adjustments
3
—
3
1
Stock-based compensation
42
26
170
95
Other expense (income), net
12
12
(81
)
(23
)
Loss on extinguishment of debt
1
1
26
13
Restructuring and related expenses
24
20
68
85
Acquisition related expenses
20
38
75
143
Adjusted EBITDA
$
828
$
735
$
3,022
$
2,384
Table 5
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
NET INCOME TO ADJUSTED NET
INCOME RECONCILIATION
(preliminary and unaudited)
Three Months Ended
Twelve Months Ended
December 31,
December 31,
(in millions, except per share
data)
2021
2020
2021
2020
Net Income Attributable to IQVIA
Holdings Inc.
$
318
$
119
$
966
$
279
Provision for income taxes
59
63
163
72
Purchase accounting amortization (1)
138
242
833
933
(Income) loss in unconsolidated
affiliates
(1
)
1
(6
)
(7
)
Income from non-controlling interests
—
11
5
29
Deferred revenue purchase accounting
adjustments
3
—
3
1
Stock-based compensation
42
26
170
95
Other expense (income), net
12
12
(81
)
(23
)
Loss on extinguishment of debt
1
1
26
13
Restructuring and related expenses
24
20
68
85
Acquisition related expenses
20
38
75
143
Adjusted Pre Tax Income
$
616
$
533
$
2,222
$
1,620
Adjusted tax expense
(120
)
(107
)
(453
)
(330
)
Income from non-controlling interests
—
(11
)
(5
)
(29
)
Minority interest effect in non-GAAP
adjustments (2)
—
(4
)
(4
)
(9
)
Adjusted Net Income
$
496
$
411
$
1,760
$
1,252
Adjusted earnings per share
attributable to common stockholders:
Basic
$
2.60
$
2.15
$
9.20
$
6.54
Diluted
$
2.55
$
2.11
$
9.03
$
6.42
Weighted average common shares
outstanding:
Basic
190.8
191.5
191.4
191.3
Diluted
194.8
195.0
195.0
195.0
(1)
Reflects all the amortization of acquired
intangible assets.
(2)
Reflects the portion of Q2 Solutions'
after-tax non-GAAP adjustments attributable to the minority
interest partner.
Table 6
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
NET CASH PROVIDED BY OPERATING
ACTIVITIES TO FREE CASH FLOW RECONCILIATION
(preliminary and unaudited)
Three Months Ended December
31,
Twelve Months Ended December
31,
(in millions)
2021
2021
Net Cash provided by Operating
Activities
$
692
$
2,942
Acquisition of property, equipment and
software
(184
)
(640
)
Free Cash Flow
$
508
$
2,302
Table 7
IQVIA HOLDINGS INC. AND
SUBSIDIARIES
CALCULATION OF GROSS AND NET
LEVERAGE RATIOS
AS OF DECEMBER 31,
2021
(preliminary and unaudited)
(in millions)
Gross Debt, net of Original Issue
Discount, as of December 31, 2021
$
12,125
Net Debt as of December 31, 2021
$
10,759
Adjusted EBITDA for the twelve months
ended December 31, 2021
$
3,022
Gross Leverage Ratio (Gross Debt/LTM
Adjusted EBITDA)
4.0x
Net Leverage Ratio (Net Debt/LTM Adjusted
EBITDA)
3.6x
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220215005373/en/
Nick Childs, IQVIA Investor Relations
(nicholas.childs@iqvia.com) +1.973.316.3828
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2024 to Oct 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Oct 2023 to Oct 2024